Keyphrases
Clinical Response
100%
Anti-tumor Necrosis Factor (anti-TNF)
100%
Ustekinumab
100%
Retrospective Chart Review
100%
Pediatric Crohn's Disease
100%
Chilblains
100%
Crohn's Disease
75%
Very Early-onset Inflammatory Bowel Disease
50%
Maintenance Dose
37%
Serum Iron Level
33%
Anemia of Inflammation
33%
Pediatric Patients
25%
Clinical Remission
25%
Genetic Susceptibility to Disease
25%
Practice Applications
25%
Pernio
20%
Patient's Weight Loss
20%
Hepcidin Assay
16%
Serum Iron Concentration
16%
Hepcidin Levels
16%
Monoclonal Antibody
12%
Pediatric Onset
12%
Disease Severity
12%
Paucity
12%
Dose Rate
12%
Previous Treatment
12%
Interleukin-12 (IL-12)
12%
Subtherapeutic
12%
Routine Maintenance
12%
Treatment Course
12%
Drug Levels
12%
Refractory Crohn's Disease
12%
Treatment History
12%
Non-response
12%
Clinical History
12%
Treatment Duration
12%
Therapeutic Drug Monitoring
12%
Interleukin-23 (IL-23)
12%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Necrosis Factor
100%
Ustekinumab
100%
Crohn's Disease
100%
Hepcidin
28%
Remission
20%
Maintenance Dose
10%
Monoclonal Antibody
10%
Prospective Study
10%
Therapeutic Drug Monitoring
10%
Interleukin 23
10%
Interleukin 12
10%
Disease Severity
10%
Medicine and Dentistry
Inflammatory Bowel Disease
100%
Pediatrics
100%
Adolescent
20%
Diagnosis
20%
Disease
20%
Gluten Free Diet
16%
Prematurity
10%
Therapeutic Agent
10%
Genetic Screening
10%
Clinical Trial
10%
Magnetic Resonance Imaging
10%
Surgery
10%
Genetic Susceptibility
10%
Biological Marker
10%
Pediatrics Patient
10%
Recurrent Disease
10%
Prevalence
10%
Disease Predisposition
10%
Lactoferrin
10%